Skip to content
Episode 135 - March 21, 2025 episode artwork

Mar 31, 2025 59 min

Episode 135 - March 21, 2025

from Biotech Hangout Hosted by Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more

On this week’s episode, Sam Fazeli, Eric Schmidt, and Brian Skorney are joined by Roivant’s Matthew Gline to discuss data, deals and the latest policy updates. The episode kicks off with concerns over potential U.S. Department of Health and Human Services (HHS) funding cuts for domestic HIV programs, with the group analyzing the impact on companies like Gilead and GSK, whose HIV prevention drugs have driven significant investor enthusiasm. They then discuss the uncertainty surrounding the new administration’s commitment to public health initiates, considering Robert F. Kennedy Jr.’s appointment as HHS Secretary and his past controversial views on vaccines and HIV prevention. The conversation then shifts to data, including positive results from Immunovant and Roivant’s Phase 3 study of batoclimab for myasthenia gravis. The group also examines the surprising absence of short sellers engaging with Roivant post-data release, highlighting shifts in biotech trading strategies. In the muscular dystrophy space, new exon-skipping therapies from Avidity and Dyne show unprecedented dystrophin restoration, suggesting potential functional benefits. However, the tragic death of a patient treated with Sarepta’s gene therapy, Elevidys, reignites concerns about accelerated approvals and the FDA’s risk-benefit calculus in rare disease research. On the deal-making front, AstraZeneca’s $425M acquisition of stealth-mode cell therapy startup EsoBiotec and Sanofi’s $600M deal with Dren Bio underscore biotech’s valuation disconnect, where early-stage private assets command premium prices while public biotechs struggle. The episode closes with insights into Alnylam’s broad label win for Amvuttra in ATTR cardiomyopathy and AstraZeneca’s $2.5B investment in biotech agreements and manufacturing in China, reflecting its long-term strategic vision despite ongoing geopolitical tensions. *This episode aired on March 21, 2025

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Episode 135 - March 21, 2025

0:00 59:46

No transcript yet.

Requests help us decide what to transcribe next.

Talking Biotech with Dr. Kevin Folta Kevin Folta Talking Biotech is a weekly podcast that uncovers the stories, ideas and research of people at the frontier of biology and engineering.Each episode explores how science and technology will transform agriculture, protect the environment, and feed 10 billion people by 2050.Interviews are led by Dr. Kevin Folta, a professor of molecular biology and genomics. State of Digital Clinical Trials Podcast Veeva State of Digital Clinical Trials is a Veeva podcast hosted by Manny Vazquez, Director, Clinical Data Strategy. Manny will be speaking to a series of expert guests from across pharma, biotech, and CROs to discuss their experiences, challenges, and ideas for the future of digital clinical trials. Will new technology make clinical trials more patient- and site-centric? The Biotech Startups Podcast Excedr The Biotech Startups Podcast by Excedr features weekly conversations with founders, scientists, and investors driving biotech innovation. Host Jon Chee dives into the challenges of building biotech startups, from pre-seed to IPO. New episodes every Monday and Thursday. Healthcare NOW Radio Podcast Network - Discussions on healthcare including technology, innovation, policy, data security, telehealth and more. Visit HealthcareNOWRadio.com Healthcare NOW Radio and Podcast Network - Radio and Podcasts for the Healthcare Industry RADIO FOR THE HEALTHCARE INDUSTRYHealthcare NOW Radio and Podcast Network offers discussions on the latest developments and trends impacting the industry including: health tech, health IT, healthcare innovation, healthcare policy, healthcare data security, telehealth, interoperability, biotech, med tech, value-based care, pharma, healthcare compliance, and much more. Shows are hosted by industry thought leaders. Guests are a "who's who" across the healthcare spectrum. The listening audience is predominantly physician and hospital-based, and the healthcare industry at large.

Frequently asked questions

How long is this episode of Biotech Hangout?

This episode is 59 minutes long.

When was this Biotech Hangout episode published?

This episode was published on March 31, 2025.

Can I download this Biotech Hangout episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.